Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer
2008

Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients

Sample size: 325 publication Evidence: moderate

Author Information

Author(s): Güth U, Huang D J, Schötzau A, Zanetti-Dällenbach R, Holzgreve W, Bitzer J, Wight E

Primary Institution: University Hospital Basel

Hypothesis

What factors contribute to non-adherence to adjuvant endocrine therapy in postmenopausal women with invasive breast cancer?

Conclusion

The study found that non-adherence to adjuvant endocrine therapy can be significantly reduced to 10.8% when patients are cared for by a specialized oncologic unit.

Supporting Evidence

  • 66.6% of patients who initiated therapy completed it.
  • 10.8% of patients showed non-adherence to therapy.
  • Patients followed by a general practitioner were more likely to be non-adherent.

Takeaway

This study shows that when doctors focus on the needs of breast cancer patients, more of them stick to their treatment.

Methodology

The study analyzed data from 325 postmenopausal women diagnosed with HR-positive invasive breast cancer between 1997 and 2003, focusing on adherence to prescribed endocrine therapy.

Potential Biases

Potential bias due to reliance on patient self-reporting and the study being conducted in a single region.

Limitations

The study relies on self-reported adherence, which may not accurately reflect actual medication intake.

Participant Demographics

The mean age of participants was 67.3 years, with a range from 47 to 95 years.

Statistical Information

P-Value

0.0088

Confidence Interval

95% CI not specified

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/sj.bjc.6604525

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication